Anchorage, ALASKA8 Active Studies

Non-Small Cell Lung Cancer Clinical Trials in Anchorage, ALASKA

Find 8 actively recruiting non-small cell lung cancer clinical trials in Anchorage, ALASKA. Connect with local research sites and explore new treatment options.

8
Active Trials
5
Sponsors
13,391
Enrolling

Recruiting Non-Small Cell Lung Cancer Studies in Anchorage

RecruitingAnchorage, ALASKANCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to ...

10,000 participants
SWOG Cancer Research Network
View Study Details
RecruitingAnchorage, ALASKANCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

1,210 participants
National Cancer Institute (NCI)
View Study Details
RecruitingAnchorage, ALASKANCT06077760

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (...

868 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAnchorage, ALASKANCT07063745

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

590 participants
Bristol-Myers Squibb
View Study Details
RecruitingAnchorage, ALASKANCT06616584

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

378 participants
SWOG Cancer Research Network
View Study Details
RecruitingAnchorage, ALASKANCT02201992

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein ca...

168 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingAnchorage, ALASKANCT06855771

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion ...

130 participants
Bristol-Myers Squibb
View Study Details
RecruitingAnchorage, ALASKANCT04310020

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy deli...

47 participants
National Cancer Institute (NCI)
View Study Details

About Non-Small Cell Lung Cancer Clinical Trials in Anchorage

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Treatment has been transformed by targeted therapies and immunotherapy based on specific genetic markers.

There are currently 8 non-small cell lung cancer clinical trials recruiting participants in Anchorage, ALASKA. These studies are seeking a combined 13,391 participants. Research is being sponsored by SWOG Cancer Research Network, National Cancer Institute (NCI), Merck Sharp & Dohme LLC and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Small Cell Lung Cancer Clinical Trials in Anchorage — FAQ

Are there non-small cell lung cancer clinical trials in Anchorage?

Yes, there are 8 non-small cell lung cancer clinical trials currently recruiting in Anchorage, ALASKA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Anchorage?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Anchorage research site will contact you about next steps.

Are clinical trials in Anchorage free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Anchorage studies also compensate for your time and travel.

What non-small cell lung cancer treatments are being tested?

The 8 active trials in Anchorage are testing new therapies including novel drugs, biologics, and treatment approaches for non-small cell lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov